Remdesivir (new indication: COVID-19; patients requiring supplemental oxygen; patients aged ≥ 4 weeks to < 12 years)

Subject:

• Active Substance: Remdesivir
• Name: Veklury®
• Therapeutic area: Coronavirus disease 2019 (COVID-19)
• Pharmaceutical company: Gilead Sciences GmbH

Time table:

• Start: 15.10.2022
• Final decision by G-BA: 06.04.2023

Final decision:

• No additional benefit proved